Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Opinion Articles

Latest Opinion Articles

"" Peter Bauza
Opinion article
Opinion article |
09 May 2019
Intellectual property and trade Research and development
Europe

Medicines shouldn’t be a luxury: it’s time to stop big pharma’s profiteering

4 min
Photograph by Yann Libessart
Opinion article
Opinion article |
07 March 2019
Research and development
Norway

Norway has invested 200 million euros in epidemic preparedness, but are they getting what they’re paying for?

5 min
MSF staff prepares a dose of an experimental vaccine Photograph by Yann Libessart
Opinion article
Opinion article |
20 October 2017
Intellectual property and trade
ASEAN

Korea must do its part for global access to affordable medicines and vaccines

5 min
Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines. Outside Ministry of Commerce, Udyog Bhawan, New Delhi Photograph by Siddharth Singh
Opinion article
Opinion article |
05 May 2017
Intellectual property and trade
IndiaPhilippinesASEAN

Intellectual property, affordable medicine, and universal health care

4 min
Counting of medication Co-Trimoxizole at the HIV clinic at Madi Opei health centre, Kitgum District, Uganda, November 3, 2009. Photograph by Brendan Bannon
Opinion article
Opinion article |
10 April 2017
Intellectual property and trade

What Japanese government can and should do for the affordable medicines in the world

Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines during the 6th round of negotiations. 3rd December 2014 Photograph by Siddharth Singh
Opinion article
Opinion article |
08 March 2017
Intellectual property and trade
India

Don’t shut down the pharmacy of the developing world

5 min
Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines. Protest was done during 6th RCEP negotiationin India, 2014. Photograph by Siddharth Singh
Opinion article
Opinion article |
02 December 2016
Intellectual property and trade
ASEAN

On World AIDS Day, threat to access to medicines looms large

4 min
Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines. Outside Ministry of Commerce, Udyog Bhawan, New Delhi Photograph by Siddharth Singh
Opinion article
Opinion article |
10 October 2016
Intellectual property and trade
ASEAN

The AIDS revolution is why ASEAN, India and China must resist controls on generic drugs

3 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury